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Abstract: Customized pharmaceutical products aim to comply with the individual needs of a patient
to enhance the treatment outcome. The current pharmaceutical production paradigm is, however,
dominated by mass production, where the pharmaceutical products embrace a one-size-fits-all de-
sign with a low possibility of treatment optimization to patient needs. This production paradigm is
not designed or intended for customized pharmaceutical products and operating this production
context for customized pharmaceutical products is argued to be cost-inefficient. To address this
challenge of inefficient production of customized pharmaceutical products, this study proposes an
approach to modular pharmaceutical product design. As a mass customization strategy, product
modularization enables serving customers with customized products cost-efficiently. The proposed
modular pharmaceutical products integrate three product design requirements originating from
patient needs: a scalable dose strength, a flexible target release profile, and a scalable treatment size.
An approach to assess the value of these product designs is presented, by means of proposing three
benefit metrics complying with respective design requirements and a cost metric assessing the cost
of producing these modular pharmaceutical product designs. Results suggest that pharmaceutical
product modularization can, by keeping the number of produced components low, substantially
increase the external product variety and, hence, enhance the treatment outcome of patients. Fur-
thermore, results indicate that the achieved benefit for the patient through product modularization
increases beyond additional costs arising during production. However, a careful modularization
must be performed to optimize the tradeoff between the increased benefit and cost.
Keywords: pharmaceutical product modularization; customized pharmaceutical products; mass
customization; product modularization; personalized medicines
1. Introduction
Personalized medicines, or customized pharmaceutical products, is an emerging field
to enhance the therapeutic outcome with patientcentricity in mind, i.e., providing the
patient with a safe and effective treatment [1–3]. Patientcentricity implies customizing
the pharmaceutical product according to design requirements complying with individual
patient needs. These individual product design requirements include active pharmaceutical
ingredient (API), dose strength, target release profile, appearance (including treatment size
and shape, for example), sensory properties, and composition [4].
However, the large-scale deployment of customized pharmaceutical products is cur-
rently inadequate. The dominating production context is mass production, where the
product design embraces a one-size-fits-all design, which means that four-to-six dose
strengths are produced in large volumes [5]. A shift toward a pharmaceutical product
customization context leads to the inevitable consequence and challenge of a vast increase
in the number of product variants produced in smaller volumes. However, a product
variety exceeding six dose strengths has been argued as infeasible in the current mass
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production paradigm [5]. Thus, uneconomical production will challenge the provision of
customized pharmaceutical products, and in the end, if the product does not reach the
patient, the therapeutic outcome cannot be enhanced.
Mass customization, as a production paradigm, has the intent of increasing business
performance by serving a wide range of customers with customized products, through
efficient production [6]. Three mass customization principles described by Hu et al. [7] in-
corporate product family architecture, reconfigurable manufacturing systems, and delayed
differentiation. Govender et al. [4] projected these into the pharmaceutical context as prod-
uct modularization, process reconfiguration, and postponement. Product modularization
in a pharmaceutical context is, to some extent, present in the literature. Siiskonen et al. [8]
have suggested an initial approach to product modularization of pharmaceutical prod-
ucts using function modeling, by which two product design requirements, originating
from patient needs, were integrated into the product: a scalable dose strength and prod-
uct size. For these modular product designs, cost and benefit studies were conducted.
Govender et al. [9] and Govender et al. [10] experimentally showed the realization of a
modular product design for a pharmaceutical product with a scalable dose strength and
flexible, but controlled, target release profile. Building on the studies by Siiskonen et al. [8],
Govender et al. [9], and Govender et al. [10], the novelty of this paper is a theoretical
modeling approach to generate modular product designs for pharmaceutical products for
cost-efficient customization. The earlier work is extended by integrating three product
design requirements into a customized pharmaceutical product: scalable dose strength,
target release profile flexibility, and scalable treatment size. The scope of this study con-
siders pharmaceutical products embracing the dosage form of a tablet, which is the most
common dosage form [5,11,12]. This study will not consider the design of the molecules of
the active pharmaceutical ingredients or excipients. Furthermore, to assess the value to
the patient of these modular product designs, models for benefit and cost are suggested
and applied. The research questions guiding this study are RQ1: How can individual product
design requirements be realized in a pharmaceutical product for customization? and RQ2: How
can the cost and benefit of customized pharmaceutical product designs be assessed?
The remainder of this paper is organized as follows: Section 2 presents essential
literature and concepts upon which this study has been built and describes the research gap
addressed in this paper. Section 3 describes the collection of methods used in the study, and
the results of applying these are presented and discussed in Section 4. Section 5 answers
the research questions posed in Section 1 and discusses the study’s methods. Section 6
concludes the paper and offers suggestions for future research directions.
2. Literature Review
In this section, a review of the essential theory and concepts is provided. The findings
are presented in the form of a research gap.
2.1. Pharmaceutical Production
The currently dominating pharmaceutical production context is mass production. A
mass production context implies batchwise production of a few product variants in large
volumes. The product design within this paradigm is even called a one-size-fits-all design,
and although some variation in dose strength for the same product is offered today, the
economic feasibility is argued to be limited to four to six product variants [5].
2.2. Pharmaceutical Product Customization
Customized pharmaceutical products allow treatments tailored to the individual needs
of the patient [5,13], which can be attributed to the biological, environmental, behavioral, or
preference characteristics of the patient [4]. Furthermore, Govender et al. [4] have outlined,
but did not present as an exhaustive set, the product design requirements of patientcentric
treatment designs to satisfy patient needs. These design requirements incorporate the API,
dose strength, target release profile, appearance, sensory properties, and composition. The
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design requirements incorporated in this paper include the dose strength and target release
profile, which are mainly attributed to the biological characteristics of the patient, as well
as appearance, more specifically focusing on the treatment size, which is attributed to the
preference category of the patient as the preferred treatment size is a variable between
individual patients [4].
Pharmaceutical product designs suitable for treatment customization have been dis-
cussed in the literature. Additive manufacturing, as a technology for patientcentric product
design, is widely researched. Within a computer model, the treatment characteristics can
be defined and then, by various techniques, be printed, providing the means for individual
customization [14,15]. Nonetheless, challenges for large-scale technical realizability of this
technology remain, such as material selection limitations, precision in process, and so forth.
Furthermore, economic feasibility issues such as large-scale production concerning cost,
time, and distribution are still unsolved [4].
Scored tablets, a commercially available product design, allow the treatment to be split
into two or four subunits [16]. Through splitting, some scalability to the dose strength is
achieved. However, the sufficiency of obtained dose strengths for a customization context
remains debatable, and in addition, for example, Wening and Breitkreutz [17] have outlined
drawbacks of splitting tablets, such as inadequate dosing and tampered release properties.
Multiple unit dosage forms, such as pellet-based dosage forms and mini-tablets,
are commercially available product concepts and have been discussed as enablers for
pharmaceutical product customization. For example, Aleksovski et al. [18] have examined
the benefits of multiple unit dosage forms regarding scalable dose strengths and flexible
target release profiles, as well as their role in alleviating swallowing difficulties. Thus far,
these product designs have purely been considered in a mass-production context rather
than in a customization context, including assessments of feasible production and provision.
These designs embrace multiple unit dosage forms consisting of several identical units and
have not been assessed with patientcentricity in mind, e.g., how to solve for providing
different product functionalities complying to patient needs but doing so cost-efficiently.
2.3. Mass Customization
A mass customization paradigm for pharmaceutical products is hypothesized as a
solution for the wide commercialization of customized pharmaceutical products. A mass
customization paradigm intends to affordably develop, produce, market, and deliver
goods satisfying a wide variety of customer needs [6,7,19]. Three mass customization
strategies (as outlined by, for example, Hu [7]) incorporate modular product architectures,
reconfigurable manufacturing systems, and postponement. Siiskonen et al. [20] studied
manufacturing system design in a customization context and suggested that the current
mass production platforms are not suitable to be operated in a mass customization context.
Siiskonen et al. [21] suggested reconfigured supply chain designs postponing the final
assembly position of the treatments closer to the customer for the cost-efficient provision
of customized pharmaceutical products. Manufacturing system design and postponement
for mass customization in a pharmaceutical context are outside the scope of this paper, but
the reader is referred to the publications by Siiskonen et al. [20] and Siiskonen et al. [21] for
further discussion on these topics.
2.3.1. Product Modularization
Product modularization is a strategy to increase the product variety for customers
while keeping the costs low [22,23]. Siiskonen et al. [8] presented a study on product modu-
larization in a pharmaceutical product customization context in which two product design
requirements, dose strength and size, were considered as the means of customization in a
pharmaceutical product. These design requirements were realized as modules that enabled
the dose strength and size scalabilities of the pharmaceutical products. Govender et al. [9]
and Govender et al. [10] manufactured experimentally modular product designs with
scalable dose strengths and flexible and controllable target release profiles.
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2.3.2. Product Architecture
According to Ulrich and Eppinger [24], product architecture is a basis for enabling
configurations of product variants. Ulrich [25] defined product architecture as the allocation
of product functions into physical components. A product is a collection of physical
elements such as components, parts, and subassemblies, and which embeds functional
elements that collectively contribute to the product’s overall function [24].
According to Du et al. [26], there are two approaches to enable variety in a product:
a modular and a scalar product architecture approach. A product embracing a modular
architecture consists of modules embedding one or more functions of the product. The
geometrical properties of the modules are fixed; however, the interactions in between
modules are kept decoupled, and this enables addition, removal, and interchangeability
of modules. Therefore, a variety of products can be obtained [27]. Scalar architecture
employs a rigid structure, in which the interfaces between the functional elements are
predefined. However, design parameters realizing the functional elements can be changed
to obtain variability in products [28]. Du et al. [26] proposed an integrated modular and
scalar architecture approach by employing the Stackelberg game theory. The configurable
component (CC) method, established by Claesson [29], is another model for an integrated
modular and scalar approach and is the one used in this study.
2.3.3. The CC Method
The CC method serves as a foundation for a product platform that provides a tool for
enabling both modular and scalar product variety; later, via platform execution, sets of
product variants can be established [29]. A common purpose for product platforms is to
establish product variety to meet a wide range of customer needs [30].
The CC method establishes a product architecture consisting of several configurable
subsystems, or configurable components (CCs), operating independently but providing
their functions to the overall performance of the system. The CC method builds on the
enhanced function-means (EF-M) modeling approach by Schachinger and Johannesson [31],
an evolution from the function–means model by Tjalve [32], where each CC object (sub-
system) is expressed by the means of functional requirements (FRs) and design solutions
(DSs). The independently operating CC objects provide a modular structure to the product.
Defining functional bandwidths of each FR and defining the design parameters of the DSs
that provide for the bandwidth of the FRs, within a CC object, enables a scalable design of
the CC and, in the end, the overall product [29].
The CC structure describes the function domain of a product platform. Levandowski
et al. [33] and Michaelis et al. [34] connected the CC objects to the component domain by
the means of a component (CO) tree of the product. The component tree aims to concretize
the abstract product architecture described through FRs and DSs by the physical realization
of the DSs assigned to the respective FRs (i.e., these are described by the means of COs
with their geometrical properties, dimensions, and so forth).
Panarotto et al. [35] researched the incorporation of nonfunctional requirements, such
as flexibility. This inclusion was achieved by defining the flexibility of the design as a
constraint (C) within the function domain. Flexibility is intended to define an adaptable,
changeable, and reconfigurable design concept of an engineering system [36]. Within
the context of this paper, flexibility of the pharmaceutical product designs indicates the
customizability of these. In this article, the dose strength scalability, target release profile
flexibility, and size scalability are assessed as the flexibility of the product designs. For
example, for dose strength scalability, the flexibility factor defined through C describes the
various dose strengths for which product variants should be configured (i.e., it is a property
across product variants but within a product family). This is different from the functional
bandwidth of a CC object (described by the means of FRs and DSs) that describes the
property of a CC object and the different variants that this CC object can be configured
as. The different variants of the CC object, rather, generate product variants belonging to
different product families. Cs are also used to limit the functional bandwidth of the CC
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objects and ultimately the product. For example, in pharmaceutical products, a C could be
the size of the treatment to ensure convenient administration, and in this case, it could be
expressed as a volume and geometrical restriction.
2.4. Value
The ultimate aim of developing designs of customized pharmaceutical products is an
increased value for the patient, i.e., increasing the benefit to the patient, however, while not
compromising the cost of doing so. To make product design decisions, Hazelrigg [37] has
stated that value should be the most intuitive criteria. Early design decisions must be based
on models describing what ultimately brings value for the customer. Value models and the
construction of these, however, have not been exhaustively investigated [38,39]. A general
definition for product value is offered by Lindstedt and Burenius [40] as the ratio between
benefits for the customer and the cost for the customer expressed in monetary terms,
time, or effort. Ulrich and Eppinger [24] use a weighted sum approach where product
performance criteria are evaluated relative to each other. In the context of customized
pharmaceutical products, Siiskonen et al. [8] presented an initial approach to their value
assessment. In this approach, the benefit was described through the number of product
variants that modular product designs could generate from a dose strength and size
scalability perspective, and the cost was described by the complexity factor by Pugh [41]. In
this study, to assess product value the concept of using cost and benefit as value assessment
criteria along with a weighted sum approach has been used.
2.4.1. Benefit
No established approach to assess the benefits of pharmaceutical product designs for
decision-making in a customization context are, to the best of our knowledge, found. In
a pharmaceutical context, the benefit of product customization describes the enhanced
treatment outcome. Examples of benefit assessment of drug products exist in the literature;
for example, Hörn et al. [42] presented a study on benefit assessment of new drug products,
where the benefits were indicated through the treatment outcome of clinical trials. These
drug products, however, resided in the realization stage, where actual clinical trials on
them could be conducted. Considering customized pharmaceutical products within the
scope of this study, the nature of these designs resides in a conceptual stage, not close to a
realization stage; thus, benefit assessment procedures must be suited to this level of early
conceptual designs.
2.4.2. Cost
Several models to assess the cost of conceptual product designs exist. Generally, the
product cost consists of material, process, and assembly costs [43]. Material and process
costs are assumed not to significantly affect the cost within the scope of this study. Rather,
the assembly cost is of interest in this research. Swift and Booker [43] have presented
an approach to assembly cost estimation which is based on handling features, fitting
techniques, and alignment features of the parts. When the process of assembly has not
been detailed, the complexity factor by Pugh [41], which essentially measures the resulting
product complexity by incorporating the number of parts, types of parts, and interfaces
between parts in an assembly, can be viewed as a pragmatic approach with which to
assess additional costs of manufacturing arising from increased product complexity. The
complexity factor has been adopted in this study to indicate the cost of manufacturing
customized pharmaceutical products.
2.5. Research Gap
Approaches to pharmaceutical product customization are emerging; for example,
additive manufacturing has been researched as a technology to achieve individualized
treatments. However, studies verifying the large-scale deployment from a technical and
economic feasibility perspective are lacking. Commercially available multiple unit dosage
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forms have been discussed as enablers for customization since these can achieve dose
strength scalability and target release profile variability. However, the product design
embraces a fully integral product even though it consists of several smaller units since
each unit is identical. Thus, the idea of introducing several units embracing different
functionalities to the overall product to comply to design requirements for a customization
context, hence employing a modular product design, is not established for multiple unit
dosage forms. Furthermore, no studies considering the cost-efficient production of these
product designs in a customization context have been found.
Product modularization has been adopted as a strategy in mass customization to pro-
vide for external product variety cost-efficiently. Product modularization is thus adopted in
this study as a hypothesis for the cost-efficient customization of pharmaceutical products.
Siiskonen et al. [8] have presented initial modular product designs of pharmaceutical
products for customization purposes, where dose strength and treatment size scalability
were demonstrated. Furthermore, this study performed an assessment of value for the
patient by suggesting benefit and cost metrics. Govender [9] and Govender [10] experi-
mentally showed the realization of modular product concepts with scalable dose strengths
and flexible target release profiles. Hence, based on the studies by Siiskonen et al. [8],
Govender [9], and Govender [10], this study presents an approach to the integration of
three product design requirements. Beyond a scalable dose strength and treatment size,
a flexible target release profile has been designed into the product, and the requirements
and consequences of integrating three product design requirements rather than two are
elicited. The aim is to assess product modularization as a strategy for a mass customization
paradigm of pharmaceutical products. This study solely considers product design and the
mass customization strategy of product modularization. For a comprehensive description
of an approach to manufacturing modular product designs, the reader is referred to [20]
and for discussion on applying the principle of postponement in a pharmaceutical context,
the reader is referred to [21].
This study, furthermore, recommends approaches to assess the value for the patient by
the means of benefit and cost metrics, which are further developed from the approach by
Siiskonen et al. [8] and comply with all three product design requirements for customization.
Finally, an approach to assess the overall value for the patient is suggested, by consolidating
the benefit and cost models into a single expression and illustrating a value-based approach
to support design decision-making regarding the best-performing modular product design
from a benefit and cost perspective.
3. Methodology
This section describes the approach to establish modular product designs for phar-
maceutical products, integrating product design requirements through the means of CC
modeling. The design of a product platform to generate treatment portfolios of different
degrees of modularization is explained. Furthermore, the selection of a model treatment
used to assess the performance of these treatment portfolios from a value-for-the-patient
perspective is presented, along with the performance assessment approach.
3.1. Configurable Component Modeling for Product Design Requirement Integration
A CC model of a treatment is established herein. A traditional design of a tablet along
with the primarily considered design requirements, dose strength, target release profile,
and size serve as inputs for establishing the CC model. These design requirements provide
a foundation for the functionalities that a pharmaceutical product should embed, and these
are expressed in FRs, which are further realized as DSs. Cs serve as means to constrain the
functioning bandwidth of any FR and their consequent DS. Cs, furthermore, describe the
nonfunctional requirements, the scalability of the dose strength, the flexibility of the target
release profile, and the scalability of the treatment size. The CC model is complemented
by a component tree of the pharmaceutical product to give physical realization to the
configurable objects in the model.
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3.2. Modeling and Executing Product Platform for Creating Treatment Portfolios
The CC model serves as a foundation for a product platform. Configurable component
modeler (CCM) [29] is a research tool for CC modeling and is used in this study to model the
product platform of the treatment. To develop the platform, the CC model is complemented
by parameter-specific data to describe the various DSs and Cs in executable terms, mainly
as integers or characters. CCM allows the execution of a product platform and does so by
solving a full-factorial combinatorial problem. The result of execution is sets of all possible
product configurations that fulfill the functional bandwidth of the FRs or nonfunctional
requirements (described through Cs) defined in the CC model.
A treatment portfolio is a set of product variants configured from CC objects created
from a single instance of parameter values on each DS in the CC model. If the CC object’s
parameter value for a DS is changed, the resulting product variants created from this CC
object belong to another treatment portfolio.
To establish dose strength scalability, target release profile flexibility, and size scala-
bility, the Cs describing these nonfunctional requirements in the CC model are defined
as bandwidths. Each treatment portfolio configures product variants so that the whole
bandwidth of the nonfunctional requirements is covered. For example, the dose strength
bandwidth is defined from 25 to 100 mg; thus, the treatment portfolio would consist of
product variants that can embrace different dose strengths in between 25 and 100 mg.
3.3. Treatment Portfolio Performance Assessment
The value for the patient of each treatment portfolio is assessed to reflect how well it
complies to the patient’s needs. To reflect the patient needs, a model treatment is selected,
and for this treatment, a treatment population reflecting the patient needs is generated.
The value of the modular pharmaceutical product designs for this treatment population is
evaluated through performance metrics. Three categories of performance metrics are used
for the value assessment: benefit, cost, and the consolidated metric value.
3.3.1. The Model Treatment and Reference Case
A reference case based on the current commercial treatment with its one-size-fits-all
design is used, to which each treatment portfolio embracing modular product designs
is compared concerning the performance metrics. Hence, this describes any increase or
decrease in performance. As a model treatment, a selective serotonin-reuptake inhibitor
(SSRI) product has been chosen that is prescribed for depression.
3.3.2. Treatment Population and Patient Segmentation
The commercial SSRI product is produced in two dose strengths: 50 and 100 mg. A
common approach to treatment with this product is to start with half a dose of a 50 mg
tablet (i.e., 25 mg); after a week, the dose is doubled to 50 mg, which is the most common
dose. Further increasing to 75 or 100 mg is common as well. The maximum dose is
200 mg [44]. Today, this treatment is produced as tablets containing the doses of 50 and
100 mg. The simplification made in this study is that the maximum dose is 100 mg.
The treatment population need is described by the optimal dose of the patients. To
model the treatment population, a random number generator was used in MATLAB,
creating a normal distribution between 25 and 100 mg, with 99.7% of the population falling
in between this dose range. Since the optimal dose of each patient is a random number in
between 25 and 100 mg, the received dose, generated by any treatment portfolio, cannot
match each patient’s dose exactly. The received dose is restricted by the available dose
strengths that the respective treatment portfolio can construct from the components used
for product variant configuration. Each patient in the treatment population is thus grouped
into their respective segment according to their received dose, and the received dose of
each patient is the next available dose that a treatment portfolio can offer by the means of
its product variants.
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3.3.3. Performance Metrics
The benefit metric aims to assess the benefits for the patient and is assessed by three
types of metrics: Bdose, Brelease, and Bsize. Each metric corresponds to the benefit for the
patient when complying with the product design requirements: dose strength scalability,
target release profile flexibility, and size scalability, respectively. The cost of each treatment
portfolio is assessed using the complexity factor by Pugh [41], which essentially evaluates
the complexity of an assembly (a product variant of a treatment portfolio). The final
performance metric, value, assesses both the benefit and cost of each treatment portfolio
by the means of a single term and is based on the concept scoring matrix by Ulrich and
Eppinger [24] to make the various treatment portfolios comparable in a normalized manner.
4. Results
This section presents the resulting CC model of a pharmaceutical product integrating
three product design requirements. Furthermore, the product platform development
procedure and the resulting treatment portfolios generated through platform execution are
described. Finally, the performance metrics constructed are presented along with the final
performance assessment of the generated treatment portfolios.
4.1. CC Model of a Pharmaceutical Product Integrating Three Design Requirements
The resulting CC model of a treatment portfolio integrating the three design require-
ments of interest in this study (dose strength, target release profile, and size) is displayed
in Figure 1. Note that this CC model only displays three product design requirements and
not the exhaustive set of design requirements required for a pharmaceutical product or
customization of the pharmaceutical product.




Figure 1. CC model of a treatment complying with three product design requirements for customi-
zation: scalable dose strength, flexible target release profile, and scalable treatment size. 
The CC API module is further composed using the CCs API core and release control 
system. Within the CC API core, the product design requirement dose strength has been 
denoted as the FRs provide therapeutic effect and define dose, to which the DSs API and API 
dose have been assigned, respectively. Within the CC API core, additional FRs are defined 
that are essential for the final realization of the API core, but not explicitly required by the 
design requirement dose strength; for example, although not crucial for the dose strength, 
an API core must contain excipients (DSs to the FR facilitate formulation) for enabling the 
formulation of the core and, in the end, ensuring the core to be producible. Furthermore, 
the API core must be defined concerning its geometrical properties, leading to the inclu-
sion of the FRs define size and define shape and their respective DSs, size and shape. 
The product design requirement target release profile is achieved through the CC 
release control system. This CC object contains the FR control drug release through top surface 
area, for which the DS lid is defined. The DS lid is further described within a CC object of 
its own. Depending on how the CC object lid is defined during physical realization, dif-
ferent release properties can be obtained. The CC object release control system further in-
corporates the FRs prevent bottom and side release and provide structural stability, which are 
solved through a single DS cup. This DS is likewise described within a CC object of its 
own, cup, and the physical realization of this will result in a component preventing any 
API release from the sides and bottom of the API core. The FR provide structural stability 
aims at giving the API core a structure into which it can be placed for controlled release. 
Two types of release mechanisms, dose-dependent release and dose-independent re-
lease, are provided through the product model. The dose-independent release scenario is 
achieved using the CC object release control system. In a scenario where this CC object is 
nonexistent, the dose-dependent release scenario is obtained instead. The dose-dependent 
release is simply performed through the inherent release properties of the API cores, a 
Figure 1. CC model of a treatment complying with three product design requirements for customiza-
tion: scalable dose strength, flexible target release profile, and scalable treatment size.
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The main FR of a treatment portfolio is to comply with the therapeutic need of any
patient, and this FR is solved by the DS treatment. This treatment is aimed to comply with
product design requirements originating from patient needs: dose strength, target release
profile, and size. The CC assembly, which essentially comprises the treatment, embodies
two FRs: provide convenient delivery and provide treatment. The first FR, provide convenient
delivery, regards processes occurring before administration to support the administration
process, whereas the second FR, provide treatment, relates to processes occurring within the
body after administration. These FRs are solved through the DSs filling system and drug
delivery system, which are further composed using lower-level CC objects, filling module and
API module. These provide the means for the independent realization of the FRs provide
convenient delivery and provide treatment.
The CC API module is further composed using the CCs API core and release control
system. Within the CC API core, the product design requirement dose strength has been
denoted as the FRs provide therapeutic effect and define dose, to which the DSs API and API
dose have been assigned, respectively. Within the CC API core, additional FRs are defined
that are essential for the final realization of the API core, but not explicitly required by the
design requirement dose strength; for example, although not crucial for the dose strength,
an API core must contain excipients (DSs to the FR facilitate formulation) for enabling the
formulation of the core and, in the end, ensuring the core to be producible. Furthermore,
the API core must be defined concerning its geometrical properties, leading to the inclusion
of the FRs define size and define shape and their respective DSs, size and shape.
The product design requirement target release profile is achieved through the CC
release control system. This CC object contains the FR control drug release through top surface
area, for which the DS lid is defined. The DS lid is further described within a CC object
of its own. Depending on how the CC object lid is defined during physical realization,
different release properties can be obtained. The CC object release control system further
incorporates the FRs prevent bottom and side release and provide structural stability, which
are solved through a single DS cup. This DS is likewise described within a CC object of its
own, cup, and the physical realization of this will result in a component preventing any
API release from the sides and bottom of the API core. The FR provide structural stability
aims at giving the API core a structure into which it can be placed for controlled release.
Two types of release mechanisms, dose-dependent release and dose-independent
release, are provided through the product model. The dose-independent release scenario is
achieved using the CC object release control system. In a scenario where this CC object is
nonexistent, the dose-dependent release scenario is obtained instead. The dose-dependent
release is simply performed through the inherent release properties of the API cores, a result
of the formulation of the cores (i.e., the API to excipient ratio, size, and shape of the cores).
The final product design requirement, size, is categorized as a property of the CC
assembly and is translated into the FR provide convenient delivery. To this FR, the DS filling
system is assigned to further be composed using the CC filling module as an autonomous
CC object.
On the highest hierarchical level, i.e., within the CC treatment portfolio, the Cs dose
range and release range describe the viable range of both properties and, hence, essentially
define the dose strength scalability and release flexibility of the treatment portfolio. The
C size range informs the allowed sizes of any treatment and thus describes the extent of
size scalability.
4.2. Component Tree and Platform Execution for Physical Realization
Figure 2 displays the realization of the respective CC object, defined in the CC model
in Figure 1, as COs within the component tree. The DSs on the lowest hierarchical level
of the CC model are connected to the COs in the component tree through is-realized-in
(iri) relationships; however, in Figure 2, only the CCs have, for the sake of brevity, been
displayed (not the breakdown of the CCs into FRs and DSs). For detailed descriptions
of the CCs, the reader is referred to Figure 1. It should be noted that several CCs are
Systems 2021, 9, 59 10 of 32
provided with a depth, such as the CC API module. The depths describe alternative CC
objects originating from assigning alternative DSs to FRs within that CC (see Figure 1).
When executing the CC model and generating the various product variants, the results are
various physical realizations of the CC object, as components, depending on the assigned
DS during the instance of execution. For example, in Figure 2, for the CO API module, six
variants of API modules are displayed; these correspond to the alternative DSs defined
in the CC model before execution. The physical realizations of the CCs API core, lid, cup,
and assembly have likewise been displayed in the component tree in Figure 2. These are
described in detail in the subsequent sections. For each CO in the tree, a figure has been
provided to give the reader a visual idea of the realized COs. It should be noted that for
the CO tablet, several examples of final assemblies configured from the set of COs are
displayed, not the exhaustive set of possible variants.
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4.3. Product Platform Design for Treatment Portfolio Generation
As described in Section 3, a model treatment, an SSRI product, has been selected as
a case example. For this model treatment, modular product designs are proposed based
on the outlined CC model of a treatment described throughout Section 4.1. Through
platform modeling and execution of the CC model, treatment portfolios containing sets
of modular product variants are generated. The platform is also used to generate the
treatment portfolios for the reference case. Their performance is assessed to evaluate the
impact of various levels of modularity that these treatment portfolios embrace on the
benefit for the patient and the cost of the product.
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4.3.1. Reference Case Design
The reference case, based on the commercial SSRI treatment, is produced in two dose
strengths: 50 and 100 mg. Figure 3 displays an illustration of the commercial treatment
with a dose strength of 50 mg. This treatment has the approximate geometrical properties
illustrated in Figure 3: an oval-formed body assuming flat faces where the body can be
divided into two end parts and a middle part (see Figure 3a). The end parts are assumed to
form a perfect cylinder with a diameter of 5 mm and height of 2 mm, d and h, respectively,
in Figure 3b. The middle part is assumed to form a cuboid with the width, w, of 4 mm and
height, h, of 2 mm (see Figure 3c). From these geometrical properties, the approximate
volume of the commercial treatment is calculated to 81.4 mm3. In this study, an assumption
is made that a tablet can be split, generating the additional dose strengths 25 and 75 mg;
the splitting line is marked in Figure 3a. A single release profile is assumed for each dose
strength. In theory, a 50 mg treatment could be established by a single 50 mg tablet or
half a 100 mg tablet. Likewise, a 75 mg treatment can be established by one and a half
50 mg tablets or half a 50 mg and half a 100 mg tablet. The preferable approach, however,
is to administer a single 50 mg tablet rather than splitting a 100 mg tablet due to the
challenges with tablet splitting (see, for example, Wening and Breitkreutz [17]); thus, the
viable approach for creating the dosages 50 and 75 mg is to minimize the number of tablet
splits. A single treatment variant is assumed for each dose strength, making the reference
case consist of, in total, four dose strengths, four release profiles, and four treatment sizes.
Systems 2021, 9, x FOR PEER REVIEW 11 of 33 
 
 
and 75 mg; the splitting line is marked in Figure 3a. A single release profile is assumed for 
each dose strength. In theory, a 50 mg treatment could be established by a single 50 mg 
tablet or half a 100 mg tablet. Likewise, a 75 mg treatment can be established by one and 
a half 50 mg tablets or half a 50 mg and half a 100 mg tablet. The preferable approach, 
however, is to administer a single 50 mg tablet rather than splitting a 100 mg tablet due to 
the challenges with tablet splitting (see, for example, Wening and Breitkreutz [17]); thus, 
the viable approach for creating the dosages 50 and 75 mg is to minimize the number of 
tablet splits. A single treatment variant is assumed for each dose strength, making the 
reference case consist of, in total, four dose strengths, four release profiles, and four treat-
ment sizes. 
 
Figure 2. Connecting the function domain to the component domain. 
 
Figure 3. (a) Illustrates the commercial tablet from the face view. (b) The end sections are displayed from the face and the 
side. (c) The middle section is displayed from the face and the side. 
  
i . ( ) i l ti i i l f t f t i .
4.3.2. Modular Product Designs
To configure modular product designs, elements are proposed to provide for the vari-
ous design requirements (these elements are denoted COs in the component tree, Figure 2).
These elements are divided into parts, modules, and assemblies, see visualizations in
Figure 4. A modular product design must be assembled through an assembly process
to generate an administrable treatment (i.e., an assembly). Parts are transferred through
a preassembly process into modules, and then modules are transferred through a final
assembly process into an assembly, see Figure 4.
— Parts
In this study, parts are the smallest elements of a treatment that serve as inputs into
the preassembly process, where these are transformed into modules. Parts include the API
cores lids and cups. The API cores comply with the design requirement dose strength (i.e.,
the cores are physical entities containing a specific dose of a specific API). Dose strength
scalability is achieved through two cores, A and B, that are smaller in size concerning dose
content than the commercial tablets. These cores are a cylindric shape and are displayed in
Figure 4, core A as yellow and core B as green. The dose content of core A is selected as
one-fifth of the smaller-sized commercial treatment, which has a dose content of 50 mg, i.e.,
the dose of core A is 10 mg. Core B is selected to contain half of the dose content of core A,
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i.e., 5 mg. To define the geometrical size of core A, the same ratio of material content as in
the commercial treatment of 50 mg is assumed. Furthermore, given that the approximate
volume of the commercial treatment is 81.4 mm3, and knowing the dose of the commercial
treatment as well as the dose of core A, the volume of core A is calculated as 16.3 mm3.
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Govender et al. [10] produced API cores experimentally using hot-melt extrusion and
melt molding. The geometrical shape of the core is a cylinder, and the diameter of the
cylinder is given as 3.81 ± 0.11 m. The core in this study is aimed at imitating these
exp rim nta ly realized cor s by Govender et al. [10]; the core diameter i defined as
2.4 mm. A smaller cor diameter is assigned in this study due to th volume restrictions
of an assembled treatment. This is discussed further below in Assemblies and treatment
portfolios. The API cores can resemble commercially available mini-tablets that have a
diameter of 2–3 mm or even smaller [45], verifying the manufacturability of the core with a
diameter of 2.4 mm. Selecting the diameter of the core, and defining the geometric shape
as a cylinder, the height can be calculated as 3.6 mm.
For core B, despite, dose-wise, being half the size of core A, the geometrical size and
shape are assumed to be equal to core A. This means that the excipient content of core B is
higher than for core A.
The design requirement of target release profile is realized by two distinct approaches.
Either a dose-dependent release is generated, which relies on the inherent release properties
of the API cores (i.e., no additional elements are introduced to realize this), or a dose-
independent release is generated by the means of a release system consisting of lids and a
cup. Two lids with different release properties, lids A and B, are considered; however, the
drug-release mechanism generated by these is outside the thesis scope. Govender et al. [10]
produced lids and cups by fused deposition modeling with a thickness of 0.5 mm, which is
used as a geometrical property in this study.
— Modules
Modules are defined as elements that serve as an input into the final assembly step
and are to be transformed into assemblies. The assemblies are the treatments provided to
patients. Modules are API cores, API modules, and filling modules. It must be noted that API
cores are considered both parts and modules since these can either be used for generating
API modules or can be directly transferred into assemblies.
API modules ar configur through the preassembly process by placing a core into
a cup and sealing with a lid (see a visual representation of API modules in Figure 4). The
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filling module has the aim of complying with the product design requirement size. The
filling module is, by itself, inert and serves the purpose of providing filling material to be
able to generate product variants of different sizes, enabling size scalability of treatments.
The geometry of the filling module is assumed to be a cylinder, and the size is assumed to
be equal to the API modules.
— Assemblies and treatment portfolios
Assemblies, or treatments, are configured through the final assembly process, where
modules are assembled into desired constellations. As displayed in Figure 4, three treat-
ment portfolios, A, B, and C, are generated through platform execution for two scenarios,
dose-dependent and dose-independent release. The treatment portfolios are initially de-
fined through the API cores used for product variant configuration. Portfolio A uses core A
in both dose-dependent and -independent release scenarios. Portfolio B uses core B, and
portfolio C uses cores A and B for both dose-dependent and -independent release scenarios.
Figure 4 displays a product variant (assembly) of each treatment portfolio; it should be
noted, however, that only a single product variant is displayed and not the exhaustive set
of product variants within each treatment portfolio.
The approach to assemble the modules into desired constellations forming the final
assemblies follows several assumptions. The assumed final allowed assembly size and
shape are in accordance with those described in the study by Siiskonen et al. [8] but
modified for the convenience of this study. In the study by Siiskonen et al. [8], a capsule
of size 00 was used as a reference into which a cuboid was placed. The volume of this
cuboid gave the maximum volume for the final assembly. The geometries of this capsule
and cuboid are used in this study to define the boundary conditions of a final assembled
treatment size. Figure 5a displays a redrawn 3D view of the cuboid that constituted the
total volume to be used by the modules in an assembly. The cuboid embraces the length,
lc, defined as the maximum length of a 00 capsule, which is 23.3 mm. Hence, a limit of
stacking five modules on top of each other (in the lc dimension) was set, which allows for a
total length of 23 mm, since the height of a module is 4.6 mm (core height of 3.6 mm and the
thicknesses of the cup and lid, 0.5 mm, respectively). Thus, the size of a treatment variant
within a product portfolio can range from a single API module to 20 modules (consisting
of both API modules and filling modules in different ratios depending on the treatment
variant). The cuboid diagonal, dc, aligns with the diameter of a 00 capsule, i.e., 8.18 mm.
The capsule periphery is displayed in Figure 5b with a dashed red line.
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for the respective scenario in 116 and 136). A smaller core can generate an increased num-
ber of dose strengths; however, this also means that an increased number of cores are 
required to configure a treatment. An increased number of cores in a treatment might, for 
higher doses, pose size restrictions implying a lower degree of size scalability. Hence, us-
ing two cores for treatment variant configuration, as for portfolio C, can give an advantage 
concerning size scalability and dose strength scalability, thus the number of product var-
iants is further increased when comparing to portfolios A and B. However, for the dose-
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calculations based on the diameter of the core, 2.4 mm, and adding the thickness of the
walls of the cup (i.e., 2 × 0.5 mm). The module stacks are stacked on top of each other
along the length, lc, dimension of the cuboid (see Figure 5c).
4.3.3. Product Variety
Through platform execution, the exhaustive set of product variants, for the complete
dose range 25 to 100 mg, within each treatment portfolio and both dose-dependent and -
independent scenarios is generated. The resulting number of product variants are displayed
in Table 1. Table 1 shows that by product modularization, and thus, by the introduction
of a few smaller components to configure the treatments from, a vast increase in product
variety can be achieved. To exemplify, instead of producing two tablets of 50 mg and
100 mg, respectively, (reference case) generating in total four product variants, producing
a single core containing 10 mg and a single filling module (portfolio A for the dose-
dependent scenario) generates in total 116 product variants, not only due to the dose
strength scalability but also, due to the size scalability. It should be noted that in both cases
two elements were produced, however, due to modularization, the number of product
variants can be significantly increased.
Table 1. Product variety for each treatment portfolio for both dose-dependent and -independent
release scenarios.
Scenario Reference Case Portfolio A Portfolio B Portfolio C
Dose-dependent 4 116 136 1540
Dose-independent 4 828 1496 27472
The product variety is created by two approaches; the first is a scaled functional
bandwidth of a function within the product but keeping the number of functions provided
by the product intact. The result of scaling the bandwidth is evident when comparing the
number of product variants of different treatment portfolios for the same scenario. For
example, the API core is scaled dose-wise, portfolio A uses a core of 10 mg, portfolio B
a core of 5 mg, and portfolio C uses both the 5 and 10 mg cores. The smaller the dose
content of the core the smaller increments of dose strengths can be obtained between
the treatment variants generating an increased number of product variants (compare
for example portfolio A and B for the dose-dependent scenario, the number of product
variants resulting for the respective scenario in 116 and 136). A smaller core can generate
an increased number of dose strengths; however, this also means that an increased number
of cores are required to configure a treatment. An increased number of cores in a treatment
might, for higher doses, pose size restrictions implying a lower degree of size scalability.
Hence, using two cores for treatment variant configuration, as for portfolio C, can give
an advantage concerning size scalability and dose strength scalability, thus the number of
product variants is further increased when comparing to portfolios A and B. However, for
the dose-dependent scenario, portfolio C can configure 1540 product variants, which is not
solely a consequence of the higher degree of dose strength and size scalability. Portfolio
C, using two cores with different inherent release properties for treatment configuration,
will provide target release profile flexibility for a fixed dose; a treatment configured from
three cores, each containing 10 mg, has a different target release profile than a treatment
configured from two cores containing 10 mg and two cores containing 5 mg, even though
the dose for both cases is the same.
The second approach to establish product variety is to introduce modules with dif-
ferent functions to satisfy design requirements. This is seen in Table 1 by comparing the
product variety of the dose-dependent and -independent release scenarios for the same
treatment portfolio. In the dose-independent release scenario lids and cups have been
introduced for the means of controlling the release providing for a vast increase in the
target release profile flexibility.
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4.4. Treatment Portfolio Performance
Product variety, although giving some indication, cannot alone describe the value for
the patient. This section will thus present the results of each treatment portfolio in terms of
value generated for the patient.
Patient Segmentation
As described in Section 3.3.2, the treatment population is divided into segments,
illustrated in Figure 6, both for the reference case (above) and the treatment portfolios
embracing modular product designs (below). The segment dose for the modular product
designs denoted in Figure 6 by A, B, M, N, and so forth, is decided according to the dose
strengths that each treatment portfolio embracing modular product designs can offer. It
should be mentioned that the illustration in Figure 6 is purely conceptual, and the sizes of
the segments, concerning the number of patients, are not correct ratios. The optimal dose
of each patient is a result on a continuous scale generated by MATLAB random number
generator. The patient is categorized into the segment offering the next available dose from
the patient’s optimal dose offered by the treatment portfolio (i.e., if the patient requires
27 mg, but the treatment portfolio can only provide a dose strength of 30 mg, the patient
will receive 30 mg and belong to the 30 mg segment).
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4.5. Benefit
This section describes the suggested benefit m trics, Bdose, Brelease, and Bsize, to s-
sess the treatment portfolio performan e from a benefit perspectiv and the utcome of
cal ulating these for ach treatment portf lio.
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4.5.1. Bdose
— Dose strength scalability
Siiskonen et al. [20] proposed an approach to assess the benefit of a treatment portfolio
concerning dose scalability by suggesting the concept of quality decay. This concept de-
scribes the distance between the dose received by the patient, decided through the patient
segmentation process, and the patient’s optimal dose. Reformulating the quality decay
concept suggested by Siiskonen et al. [20], Bdose aims to assess how close the dose offered
by a treatment portfolio is to the patient’s optimal dose.
To assess the benefit from a dose strength scalability perspective, Bdose is calculated
through Equation (1). In this equation, Doseoptimal, m is the optimal dose of each patient m,
Doserec, m is the dose received by the patient decided through the patient’s segment, and








∣∣∣Doserec, m − Doseoptimal,m∣∣∣
Doseoptimal,m
 (1)
Figure 7 depicts the increase in the Bdose metric in percentage when comparing each
treatment portfolio embracing modular product designs, A to C, to the reference case.
It is inevitable that, through product modularization, the dose strength of the treatment
offered to the patient is better matched with the patient’s optimal dose. If studying the
raw numbers for Bdose, displayed in Table A1 in Appendix A, the match of the received
dose to the optimal dose of the patient is 0.92 for portfolio A and 0.96 for portfolios B and
C. The reference case results in 0.79, and 1.0 denotes a perfect match. This substantial
improvement in dose match might not be as evident if solely displaying the increase from
the reference to the modular product designs in percentage. 
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Figure 7. The increase in benefit from a dose strength perspective when comparing each treatment
portfolio embracing a modular product design to the reference case.
The driver for improved quality from a dose strength perspective is the dose content
of the API core as this decides the dose strength increments between each treatment variant
in a portfolio. The smaller the dose content of the API core, the better the dose strength
received by the patient can be matched to the patient’s optimal dose, and, hence, the
performance of Bdose is increased. Portfolios B and C show the same level of increase in the
Bdose metric. The reason is that, even though the level of scalability is higher for portfolio
C than B (i.e., using API cores of two dose strengths for generating product variants), it is
still the smallest core that, dose-wise, decides the final performance on this metric. The
smallest core decides the smallest dose increments that can be obtained.
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4.5.2. Brelease
— Target release profile flexibility
The target release profile flexibility, Brelease, is assessed through Equation (2). Pa-
tient segmentation decides the dose that a patient receives, and given this dose strength,
the number of release profiles a patient can choose from is assessed. In Equation (2),
Release variantssegment describes the number of release variants each treatment portfolio
can configure for each patient segment, and xsegment describes the ratio of patients within
each segment, which is obtained through Equation (3). In this equation, Populationsegment
describes the number of patients within a segment, and Populationtotal describes the size










The results of the Brelease metric is displayed in Figure 8. The increase in percentage
when comparing the modular product designs to the reference case is depicted. The
increase in target release profile flexibility is shown for both the dose-dependent scenario
(i.e., relying on the inherent release properties of the API cores) and the dose-independent
scenario (i.e., controlling the release through the release control system). By modularizing
the product and only introducing a few different parts to it, the number of release profiles
can be substantially increased. When studying portfolio C for dose-dependent release,
solely relying on the inherent properties of the API cores, the number of release profiles a
patient can choose from is increased by more than 600% when compared to the reference
case. Studying the raw numbers of Brelease (see Table A1 in Appendix A), the reference case
can generate a single release profile for each dose strength, whereas portfolio C can generate
an average of 7.23 release profiles. This increase in release profiles is achieved by using
two API cores for product variant configuration instead of a single core. When studying
the independent-release scenarios, portfolio A can generate, on average, 7.75 release
profiles, and portfolios B and C can generate 14.0 release profiles, on average. These
increases correspond to 675% and 1300% and are achieved entirely by either introducing
two additional types of components, a lid and a cup (portfolio A) or three additional types
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It should be noted that for portfolios A and B, for the dose-dependent scenario, there
is no increase in the Bdose metric. The reason is that, even though portfolio B can, from a
dose-strength perspective, provide an increased number of product variants compared to
portfolio A, these portfolios can, when fixing the dose, from a release perspective, solely
configure a single target release profile. For dose-dependent release, the release profile
relies solely on the API core combination creating the product variants, and portfolios A
and B use a single API core, in the respective case, for the creation of the product variants
for each dose strength.
Portfolios B and C are different from a dose-dependent release perspective, even
though, from a dose-independent perspective, they are identical. From a dose-independent
perspective, the lids control the release rate. This means that it does not matter if one
configures one’s treatment of 25 mg consisting, API core-wise, of five 5 mg cores or two
10 mg cores and a single 5 mg core. Only the unique combinations of the lids for each dose
strength act as the driver of the product variety in the dose-independent release scenario.
4.5.3. Bsize
— Size scalability
The third metric, Bsize, is calculated through Equation (4) and assesses the size scala-
bility of a treatment portfolio. As an indicator for size scalability, the number of treatment
sizes, given a fixed dose and target release profile of the patient, is used. In Equation (4),
Avg. Size variantssegment denotes the average number of different sizes that a treatment
variant can be configured as when the dose strength and target release profile are fixed.
Several treatment sizes are obtained for each variant within a patient segment with different
target release profiles; thus, the average number of size variants is calculated. For example,
for portfolio C, a dose strength of 25 mg can be obtained by the means of different cores.
Regardless of whether a dose-dependent or -independent scenario is considered, several
target release profiles can be configured for the dose strength 25 mg, and for all these,
different-sized treatments can be configured. To obtain a single value representing the
number of size variants for each segment, the average of the number of size variants for
each segment is calculated.
The number of treatment sizes is constrained concerning the shape and volume of the
final assembly, as described in Section 4.3.2. In Equation (4), xsegment describes the ratio of





xsegment × Avg.Size variantssegment (4)
The results of the Bsize metric are displayed in Figure 9, where, as with the preceding
benefit metrics, the percentage increase is presented when comparing the modular product
designs to the reference case. Overall, similarly to the Brelease metric, substantial increases
in the number of product variants offered for the patient to choose from can be obtained
simply by just introducing an additional module, a filling module, to provide size scalability.
Studying the raw data of Bsize (see Table A1 in Appendix A), the reference case can offer
a single treatment size for each dose strength, whereas portfolio A can, on average, offer
14.25, portfolio B 8.0, and portfolio C 11.13. These numbers correspond to increases of
1330%, 700%, and 1010%, respectively.
Portfolio B shows the smallest increase in Bsize. The reason is that the geometrical size
of API core B, which is used for configuring the product variants of portfolio B, is the same
as for API core A (used in portfolios A and C), however, API core B contains only half the
dose content of the API core A. Thus, the configured treatments of portfolio B are larger in
size compared with, especially, portfolio A when configuring treatments of the same dose
strength. In addition, since there is an upper limit in treatment size, the size scalability by
the means of filling modules is much lower for portfolio B than for A since the remaining
volume to fill by filling modules for treatments of portfolio B is much smaller. The same
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reason applies when considering the size scalability of portfolio C compared to portfolio A.
Portfolio C poses some increased level of size scalability compared to portfolio B due to
using both API cores A and B for product variant configuration. Hence, for a fixed dose,
portfolio C can configure several sizes of treatment variants by varying the API cores A
and B; on average, the remaining volume of the treatments within which to vary the filling
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4.5.4. Patient Benefit Exemplification
To describe the meaning of an increased patient benefit by the means of modular
product designs, an exemplification is offered in Figure 10.
In Figure 10, the example of treatments that a patient requiring the dose strength of
34.3 mg can be offered in the respective scenario is illustrated. The reference case displays
the current mass production paradigm, where the patient receives a dose of 50 mg. The
resulting treatment outcome from a dose perspective, Bdose, is 0.54. Furthermore, this
patient is limited to a single target release profile and treatment size, i.e., the values for
Brelease and Bsize are 1.
The selection of treatments offered to the patient from portfolio C for both the dose-
dependent and -independent scenarios are displayed in Figure 10. Note that not the
exhaustive set of treatment choices have been illustrated. For both scenarios, the benefit
from a dose perspective, Bdose, can be increased to 0.98. For the dose-dependent scenario,
the patient has eight target release profiles to select from. In a dose-independent scenario,
the selection of the number of target release profiles is increased to 40. Furthermore,
portfolio C can at an average offer the patient a selection of 15.5 treatment sizes. An average
number for treatment sizes is displayed since the treatment variants posing different release
properties, i.e., D1 to D8 or I1 to I40 poses different size scalability properties. For example,
the degree of size scalability of treatment D8 is not as large as for treatment D1 due to the
former configuring a larger treatment from the API cores alone before the filling modules
for size scalability is introduced.
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4.6. Cost Model
Equation (5) displays the total cost, Ctotal , of a treatment portfolio. In this equation,
c fpre is the preassembly cost, and c f f inal is the final assembly cost; both these expressions
are based on the complexity factor by Pugh [41].
Ctotal = c fpre + c f f inal (5)
4.6.1. Preassembly Cost
The preassembly cost, c fpre, is only applicable in the dose-independent scenario since
the preassembly process is therein used to transform API cores, lids and cups, into API
modules (see Figure 4). The preassembly cost, c fpre, is obtained through Equation (6), where
Npparts is the number of parts in an API module, Niparts is the number of interfaces between







4.6.2. Final Assembly Cost
The final assembly cost, c f f inal , is obtained through Equation (7) and is applicable to
the process of transforming modules into assemblies (see Figure 4).















In Equation (7), Npmod, Nimod, and Ntmod are the number of modules, interfaces
between the modules, and types of modules, respectively, calculated for each unique
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product variant within each patient segment for each treatment portfolio, both for dose-
dependent and -independent scenarios. The expression is averaged by the number of
product variants, Variantssegment, within each segment. Finally, for each treatment portfolio,
a weighted average is calculated for c f f inal using the patient segment fraction of the total
treatment population, xsegment, obtained through Equation (3).
In Equations (6) and (7), K is the constant of convenience, and f is the number of
functions within the assembly for which the cost is evaluated.
4.6.3. Cost Assessment
The cost assessment is performed for both the reference case and the respective
portfolio embracing modular product designs. The result is displayed as a change in cost
when comparing each portfolio embracing modular product designs to the reference case,
respectively, for both dose-dependent and -independent scenarios.
— Reference case cost assessment
As mentioned, the reference case is based on a commercial treatment providing two
tablets containing the dose strengths 50 and 100 mg. A split tablet not only generates
additional dose strengths, but also an imaginary interface is introduced to perform cost
estimates on the commercial treatment by using Equation (7). This imaginary interface
aligns with the splitting line, displayed in Figure 3a. If this imaginary interface were
not introduced, Equation (7) could not be used for cost assessment since the number of
interfaces, Ni, would be equal to zero, making the expression in Equation (7) zero. Hence,
the result of the reference case would not be comparable with the cost of the treatment
portfolios embracing modular product designs.
— Modular product design cost assessment
The preassembly cost, c fpre, obtained through Equation (6), is equal for each treatment
portfolio (for the dose-independent scenario); since each API module consists of three parts
(an API core, a lid, and a cup), the assembly of the parts is fixed, and, in this study, three
interfaces are assumed (one between each part). Finally, the API module is configured of
three types of parts since each part in the API module is a type of its own.
To perform a final cost assessment, the sets of product variants in each treatment port-
folio obtained through platform execution are used. The output from platform execution
describes the Npmod and Ntmod for each product variant within each treatment portfolio. To
calculate the number of interfaces, Nimod, within each assembly (product variant) of each
treatment portfolio, the final configuration of the assembled treatment must be known. In
Section 4.3.2, the approach of assembling the treatments into desired module constellations
is described. Based on the module constellations in an assembly, the number of interfaces
between the modules is calculated by Equation (8).
Nimod = (NMS − 1)× NSS + (NSS − 1)× NMS + 2NMPNS − 1 (8)
In Equation (8), NMS is the number of modules in a stack, and NSS is the number
of saturated stacks (a full arrangement of four modules) placed on top of each other, as
displayed in Figure 5c. NMPNS is the number of modules in any non-saturated stack.
According to Pugh [41], the product NpNiNt, in both Equations (6) and (7), is the
cost driver; thus, the focus is directed to this product in the modeling. Hence, K, which,
in Equations (6) and (7), is a constant of convenience, is set to one. f denotes the number
of functions of the product; thus, the complexity factor essentially indicates the cost
per function. However, in this study, the number of functions is set to one when using
Equations (6) and (7). The reason is that the functions embedded by any treatment portfolio
will be the same, since the idea is to propose treatment portfolios complying with each of
the design requirements: dose strength scalability, target release profile flexibility, and size
scalability. These design requirements are the primary functions embodied by the product
design, providing value for the patient.
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Figure 11 displays the resulting increase in the cost of each treatment portfolio for
both dose-dependent and -independent scenarios. Since the cost of any treatment portfolio
embracing modular product designs is calculated as a change compared to the reference
case, it is evident that portfolios consisting of modular product designs will increase the
cost of production. In addition, an increased level of modularization will increase the
cost of production. For example, when comparing portfolio A to portfolio B, the API core
in portfolio B entails a smaller dose than the API core of portfolio A. The consequence is
that portfolio B requires more API cores in an assembly to generate product variants of the
same dose strength as portfolio A, hence increasing the value of Npmod in Equation (7).
When comparing portfolios B and C, portfolio C does not necessarily require as many
API cores for generating a specific dose strength as portfolio B since portfolio C has two
API core sizes to use for configuration. However, due to portfolio C using two cores for
configuration, the value for Ntmod in Equation (7) is increased, and thus, overall, the final
cost of portfolio C is higher than that for portfolio B. The difference in cost when comparing
the dose-dependent and dose-independent scenarios for the respective treatment portfolio
is due to the preassembly cost, which is added in the dose-independent scenario.
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Figure 11. The increase in cost when comparing each treatment portfolio embracing a modular
product design to the reference case.
4.7. Value Model
Overall, when studying the benefit and cost metrics, the cost increases for the treatment
portfolios are between ~450 and 800% compared to the reference case, whereas the increase
in benefit metrics, especially for Brelease and Bsize, can approach and exceed values of
~1300%. This might give some indication that the benefit of modular product designs
increases faster than their production cost. However, the benefit and cost metrics are not
directly comparable as they currently stand.
To enable weighing the cost to benefit, an approach to assess the value of each treat-
ment portfolio is suggested. Based on the concept scoring method by Ulrich and Ep-
pinger [24], the final value, V, of each treatment portfolio is calculated through Equation (9).
V = wbene f it
∑ Bene f it
Nr o f bene f it metrics
+ wcost
∑ Cost
Nr o f cost metrics
(9)
In Equation (9), ∑ Bene f it is the sum of each benefit metric and is, in Equation (9),
described for each treatment portfolio by a score on a scale of 1 to 5. Similarly, ∑ Cost
is a score on a scale of one to five. To distribute scores for the benefit and cost metrics in
Equation (9), a scale for each performance metric has been constructed. These scales are
based on raw data obtained when calculating the performance metrics for each treatment
portfolio. This raw data can be found in Table A1 in Appendix A. For each performance
metric, the highest and lowest performances, across the treatment portfolios, have been
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used in between to establish a linear relationship. To exemplify a scale, Figure 12 presents
the scale for the Bdose metric. The reference case performs the worst on this metric, i.e.,
Bdose = 0.7909 for which the score p = 1 is assigned. Portfolios B and C perform the best on
this metric, i.e., Bdose = 0.9581 for which the score p = 5 is assigned. A linear relationship is
established in between these metric values and scores (see Figure 12), and the remaining
portfolio performances are evaluated on this linear scale to be assigned a score. Thus,
the final score on each performance metric that each treatment portfolio obtains depends
on how well the treatment portfolios perform (i.e., where they end up on the scale). The
remaining scales for the performance metrics and the final scores of each treatment portfolio
on each performance metric are found in Figures A1–A4 in Appendix B and Table A2 in
Appendix C, respectively.
Figure 12. Exemplifying scales for scoring Bdose in the final value assessment.
The scores obtained for the benefit and cost metrics that each treatment portfolio
achieves are divided by the number of either benefit or cost metrics (i.e., Nr o f bene f it metrics
or Nr o f cost metrics), respectively, to obtain an average score of both benefit and cost.
Furthermore, the benefit and cost metrics are weighted to explore cases where either the
benefit and cost are weighted equally or where either the benefit or the cost is emphasized.
The weighting is determined through the weight factors in Equation (9), wbene f it and wcost.
The cases explored are illustrated in Table 2 where, in the Value 50–50 case, the cost and
benefit are weighted equally; in the Value 67–33 case, the benefit is emphasized; and, finally,
in the Value 33–67 case, the cost is emphasized.
Table 2. Weight factors to explore different emphases on cost and benefit.
Case wbenefit wcost
Value 50–50 0.5 0.5
Value 67–33 0.67 0.33
Value 33–67 0.33 0.67
Value Assessment
Table 3 presents the value of each treatment portfolio for both dose-dependent and
-independent release scenarios. Furthermore, based on the resulting value of each treatment
portfolio, to get a quick sense of how the treatment portfolios compare to each other, a
ranking has been assigned when comparing the resulting values.
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Table 3. The final value of each treatment portfolio and ranking between the portfolios.
Case Reference
Dependent Release Independent Release
Portfolio A Portfolio B Portfolio C Portfolio A Portfolio B Portfolio C
Value 50–50 3 2.98 2.60 2.95 2.87 2.80 2.84
Ranking 1 2 7 3 4 6 5
Value 67–33 2.32 3.10 2.75 3.31 3.26 3.34 3.47
Ranking 7 5 6 3 4 2 1
Value 33–67 3.68 2.86 2.45 2.60 2.48 2.27 2.22
Ranking 1 2 5 3 4 6 7
When the cost and benefit are equally emphasized (i.e., Value 50–50 case), the reference
case is resulting in the highest value followed by portfolios A and C for the dose-dependent
release scenario. Portfolio A and C performs well on the Bdose and Bsize metrics but poorly
on the cost metric, whereas the reference case maximizes the cost metric but performs
poorly on the benefit metrics. Since the benefit term of the value equation is an average
of each benefit metric, the overall benefit term will suffer when the performance is not
maximized on each of the benefit metric. For example, portfolios A and C for the dose-
dependent release scenario maximizes or performs well on the Bdose and Bsize metrics,
but since the performance on the Brelease metric is worse, the overall benefit term suffers
noticeably even though the Bdose and Bsize metrics are significantly better for portfolios A
and C compared to the reference case.
An increased modularization (moving from portfolio A to portfolio C) can result in
a benefit exceeding the cost, however, the benefit must be emphasized prior to cost (i.e.,
Value 67–33 case). The reason for this can be seen in Figures 7–9, where an evident increase
in benefits can be obtained through modular product designs. Especially when comparing
portfolios A, B, and C, in the dose-independent release scenario, an increased value can be
seen by increased degree of modularization. Even the dose-independent release scenario
of portfolio C exceeds the dose-dependent scenario of portfolio A in value due to the vast
increase in benefit resulting from product modularization.
When emphasizing cost prior to benefit (i.e., Value 33–67 case) a low degree of mod-
ularization is suggestively resulting in higher value. When, for example, comparing
portfolios A to C for the dose-independent release scenario, the final value of portfolio C
is lower than for A and B, which could suggest that the cost of increased modularization
exceeds its benefits.
5. Discussion
To answer the research question RQ1: How can individual product design requirements be
realized in a pharmaceutical product for customization? the CC method was proposed as an
approach to integrate product design requirements as functions into the pharmaceutical
product. The usability of this approach has been demonstrated by developing a CC
model of a treatment integrating the design requirements of dose strength, target release
profile, and size. By using the independently operating CC objects, these separate design
requirements have been incorporated as functions in the overall product. As these CC
objects operate independently, a modular approach to variety has been presented, i.e., an
overall treatment can be configured by using or not using each CC object depending on the
design requirements to which the treatment must comply.
The API core was introduced to satisfy the design requirement dose strength. To
incorporate the design requirement target release profile, two approaches to realization were
discussed; the first relies on the inherent release properties of the API cores (dose-dependent
release), and the second approach introduces a release control system by means of lids and
cups (dose-independent release). Finally, the filling module was introduced to satisfy the
design requirement size.
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Not only were these design requirements incorporated, but so were the desired
properties of these design requirements, i.e., a scalable dose strength, a flexible target release
profile, and a scalable treatment size. Achieving flexibility in these design requirements
enables the customization of the treatment according to the individual needs of the patients.
The flexibility of the design requirements has been realized through the scalable approach
to product variety. For example, a scalable dose strength is achieved by introducing API
cores with a low dose content, and by varying the number of API cores in a treatment,
the dose strength of the treatments can be varied. Furthermore, different sizes of API
cores were introduced to further increase product variety. A decreased dose content of
the API core increases the dose strength scalability. Lowering the dose content raises two
considerations, though. If the dose content is decreased but the overall material content of
the treatment remains fixed, the API core size decreases in proportion, and this means that
the manufacturability of these must be verified. The second consideration is to keep the
API core size to ensure their manufacturability. Hence, the material content of the core is
changed, resulting in a decreased dose content. The case study in this paper is, however,
purely theoretical and serves the purpose of testing the usability of the proposed method
of generating modular product designs for pharmaceutical products, and rather describes
the approach to increase the scalability of the treatment dose strength. API core design
concerning limits in sizes and dose content, the manufacturability of these as well as the
resulting dose strength scalability is product specific and depends on the API to excipient
ratio. Thus, the dose strength scalability shall be investigated for each product separately.
The challenge of configuring treatments (final assemblies) embracing higher dose contents
arises since, for the convenience of administering any treatment, an upper size limit exists.
This study did, however, only explore two different sizes of API cores to determine any
indication of the benefit and cost of the resulting treatments. This study did not, by any
means, aim to optimize the size(s) of the API cores or the number of different-sized API cores
that should be incorporated in a treatment portfolio for the optimized benefit and cost.
Target release profile flexibility is obtained by two approaches. The first scenario is
relying on the dose dependency of the release (i.e., depending on the API-to-excipient
ratio of the API core) as well as the size and the shape. The resulting release mechanism
has not been studied and is left for future work. The other scenario is dose-independent
release, which is controlled, and the product variety can be increased vastly, since this
approach relies on the release properties of lids. The lids ensure that the release is slower
than through the cores, meaning that the lids control the release. This study has only
explored the consequence on benefit and cost of introducing lids with two different release
properties. This study did not study the explicit manufacturing process of the lids, the
release mechanism of the lids and the obtained release window of treatment through
varying the lids but should be in future studies.
The scalable size property was realized by scaling the number of filling modules. A
single size of a filling module was used, and the number was varied within the limits of a
maximum treatment volume, described in Section 4.3.2. This study aimed to explore the
size scalability property and suggest an approach to achieve this. The preferred size or
shape of a treatment for any specific patient is outside the scope of this research.
This study demonstrated the applicability of the method by integrating three design
requirements, dose strength, target release profile, and treatment size, for the means of
pharmaceutical product customization. This study has not integrated the exhaustive set
of design requirements; however, the CC method is general and can be used to integrate
any desired design requirement by translating the design requirement into a functional
requirement and searching for design solutions to this. This way the CC method can
likewise be used to develop function models of pharmaceutical products, beyond the
dosage form of a tablet, by focusing on the functions required for the specific dosage
form of interest. CCM was used to develop a platform basing on the CC model of the
pharmaceutical product. CCM is a research tool and due to its limitations support was
brought from MATLAB to, for example, eliminate unfeasible solutions and to perform
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benefit, cost, and value assessments. Hence, this approach to platform modeling does not
offer a complete solution applicable in the industry yet, however, a basis and a concept is
presented to be further developed into a robust tool for usage in the industry.
To answer the second research question, How can the cost and benefit of customized phar-
maceutical product designs be assessed?, this study proposed three categories of performance
metrics—benefit, cost, and value—to assess the value for the patient when redesigning
the pharmaceutical product to comply with patient design requirements. To assess the
performance, the CC model was developed into a platform based on a commercial SSRI
treatment, and through platform execution treatment, portfolios A, B, and C, embracing
modular product designs, were generated. Three metrics were proposed within the benefit
category: Bdose, Brelease, and Bsize. Bdose complies to the design requirement of dose strength
scalability and adapts the concept of quality decay, which was initially suggested by Siisko-
nen et al. [20]. This metric describes how closely the dose received by the patient matches
the patient’s optimal dose. How to define the optimal dose of the patient is a question that
belongs to the diagnostic field of research and is outside the scope of this study. However,
in this study, based on the selected model treatment, a fictitious treatment population was
generated following a normal distribution between 25 mg and 100 mg for the means of
illustrating the usability of the described model.
The second benefit metric, Brelease, was proposed to assess the target release profile
flexibility of the treatment portfolios. This metric assesses the unique number of release
profiles a patient with a predefined dose can choose from. As an initial suggestion, this term
can indicate the improved treatment quality concerning target release profiles by using
the increase in the number of release profiles. However, future work should be conducted
to, for example, construct a metric that can describe the release profile window that it
is possible to create from the components of the treatments and then assess the distance
between the optimal release profile of the patient and the release profile that actually can
be generated for the patient by the treatment portfolios.
The third benefit metric, Bsize, was an initial suggestion to assess the size scalability
of treatments within a treatment portfolio; for this, the number of treatment sizes that a
patient, given a preselected dose and target release profile, can choose from is used as an
indication for improved treatment quality. Future work should, however, incorporate the
design of an assessment procedure where the optimal size and shape of treatment for the
patient and the size and shape received by the patient can be compared.
To assess the cost of the treatment portfolio, the complexity factor by Pugh [41] was
used as a proxy. This factor indicated additional costs arising from the manufacturing of
more complex product designs (i.e., modular products instead of fully integral products,
as the reference case represents). In this study, the reference case (a fully integral product,
meaning it is not composed of several parts or modules) does not entail any interfaces
between the modules, since no modules exist to create any interfaces. Hence, the cost
estimate using the complexity factor in Equation (7) cannot directly be used to give a com-
parative number to which modular product designs can be compared since the resulting
complexity factor for a fully integral product is zero. By introducing an imaginary interface
to the product design of the reference case, the complexity factor was used as an estimate
indicating cost; however, with this approach, the complexity factor is overestimated, which
might indicate an overestimation of the cost. On the other hand, the inclusion of the imagi-
nary interface also allows for tablet splitting, which generates additional dose strengths
for the reference case; similarly, this overestimates the benefit of the reference treatment
portfolio. As an initial suggestion of cost assessment, this overestimation of both the cost
and benefit was accepted; however, the complexity factor is an initial pragmatic estimate
for design concepts to indicate the cost. The complexity factor by Pugh [41] is based on
discrete part products. In the current mass production context, pharmaceutical products
embrace a composite type of nature rather than being discrete part products. However,
the approach to product modularization for pharmaceutical products is inspired by dis-
crete part products, especially modular product architectures that have been established
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for product customization purposes. Thus, the complexity factor, likewise inspired by
assessments performed on discrete part products, has been used to assess the increase in
cost when generating modular architectures for pharmaceutical products. The complexity
factor has been used as an indicative measure, measuring a change when comparing the
reference case to any modular product design case. The complexity factor has not been
used to describe any absolute increase in cost. To determine if the complexity factor is
the right approach to assess the cost of modular pharmaceutical products is not further
discussed. Detailed cost models should, however, be constructed when more knowledge
about the product is acquired, the material selections are made, and the manufacturing
processes are outlined and so forth. The scope of this study, however, extended to modular
product design; hence, the consideration of actual material selection, the selection of manu-
facturing processes from a cost-efficiency and technical realizability perspective has not
been incorporated; however, this shall be addressed in future research.
The value assessment approach for each treatment portfolio has been suggested to
weigh the benefits to the cost. Scales were created based on the raw performance data of
each treatment portfolio on the respective performance metric. The scales were established
to follow a purely linear scoring system between the lowest- and highest-performing
portfolio on the respective metric. Whether the scales should be designed to follow linear
relationships was not further studied; however, for sensitivity purposes, future experiments
could be conducted to determine if any other type of scales (for example, following
multiplicative or exponential relationships) will change the resulting value assessment.
The expression for value consists of two distinct terms: benefit and cost. The benefit
term consisted of the three performance metrics Bdose, Brelease, and Bsize. These have in this
study been equally weighted in the expression for value. However, future studies can
consider the weighting of these benefit metrics in relation to each other depending on the
patient preference; this can provide the basis for the selection of the most suitable treatment
for that patient.
Since the cost term only consists of a single metric, no inherent weighting must be
considered for this term. Nonetheless, the benefit and cost terms were weighted against
each other to create cases that either weigh the benefit and cost equally or emphasize either
the benefit or the cost (i.e., the cases Value 50–50, Value 67–33, and Value 33–67). These
cases have been created for the sole purpose of testing the impact in the resulting value
metrics of the respective treatment portfolio. To determine whether the correct weights
have been assigned was not the objective of this study. The value model was kept general,
and essentially the stakeholders responsible for designing the products must choose the
weighting to suit their respective business models.
Overall, to increase the value for the patient, modular product designs could be used to
integrate desired design requirements into treatments, resulting in substantially increased
performance concerning the benefit metrics, especially Brelease and Bsize. However, these
benefit metrics measured the number of variants for the patient to choose from while fixing
the dose of the patient. Clarifying the optimal target release profile and treatment size of
the patient, as well as the offered target release profile and the treatment sizes by their
portfolios, would allow to investigate the match between the optimal and the offered target
release profile and size, respectively. This match would better reveal the actual increase in
the benefit metrics Brelease and Bsize and reveal if the increase in performance, magnitude-
wise, can reach the values that resulted from the approach to assess the performance in
this study. In addition, the cost of producing modular products, posing increased benefits,
increases in a similar trend. Thus, further studies should consider the tradeoff between the
increased benefit for the patient and the increased cost of production. Ultimately, a better
treatment could cost more due to its benefits, but the question remains of how much more
is viable from a business perspective.
In this study, the benefit for the patient has solely considered benefits from a single
treatment perspective. Product modularization offers another significant opportunity,
combination therapeutics. Polypharmacy, i.e., administering multiple medications in a day,
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has been discussed as a reason for nonadherence especially for an ageing population [46].
Modular pharmaceutical product designs could offer a solution to nonadherence from
polypharmacy since instead of administering multiple treatments, the treatments could be
combined as modules into a single treatment and thus, improve the adherence rate.
Increased modularity (i.e., from portfolio A to C) displayed an overall improved
performance concerning benefits, mainly from a dose strength and target release profile
perspective. However, when regarding the benefit from a size scalability perspective a
lower degree of modularization is preferable due to the size restriction of the final treatment.
The key is to consciously design the modules to find the balance that results in a degree of
modularization that, from a cost and benefit perspective, provides the best outcome. To
develop this optimal design will probably be a case-by-case consideration, and any further
discussion of this is outside the scope of this paper. Not only is the trade-off between
benefit for the patient and the cost of production a key consideration when modularizing
products; pharmaceutical production is a highly regulated environment that currently
poses strict approaches for the quality control of any commercial pharmaceutical product.
The approaches to quality control today generally imply an off-line quality control of each
batch produced. Employing current quality control approaches with increased product
modularity and the resulting increase in complexity of production logically implies an
increased degree of quality control activities. The management of the required increase of
quality control activities remains a challenge. Hence, the challenge of quality control for
customized pharmaceutical products is researched and for notable research initiatives on
the topics such as quality by design and process analytical technology for real-time quality
control the reader is referred to [47].
6. Conclusions and Future Work
This paper presented an approach to integrate three product design requirements—
dose strength, target release profile, and size—to customize pharmaceutical products
according to patient needs. The CC method enabled the integration of these design
requirements as functions to which design solutions were assigned and, further, which
were developed into independently operating CC objects. These CC objects were further
realized as components that generated modular product designs.
The API core was introduced to satisfy the design requirement of dose strength, the lid
and cup were used to meet the design requirement of target release profile, and the filling
module was employed to fulfill the design requirement of size. To achieve the desired
flexibility of these design requirements, scalable parameters of the design solutions were
defined. For example, by introducing an API core with low dose content, the number of
these cores could be scaled to generate treatments of different dose strengths.
An SSRI treatment was selected as a model treatment for which a platform was
developed, based on the CC model of a treatment. Through platform execution, treatment
portfolios were generated. Portfolios A, B, and C embraced modular product designs, with
varying degrees of modularization, and the design of the reference case was based on the
model treatment. Furthermore, a patient population for this model treatment described
by patient needs was developed. The value of the treatment portfolios for the patient was
assessed through three categories of performance metrics: benefit, cost, and value. From a
benefit perspective, three metrics were suggested to comply with the three product design
requirements: dose strength scalability, target release profile flexibility, and size scalability,
respectively. The results showed that
— Increased degree of modularization can substantially increase the ability to match the
offered treatment to the patient’s optimal dose.
— By introducing a few components to increase target release profile flexibility, there is a
substantial increase in the number of target release profiles from which the patient
can choose.
— Maximizing the dose content of the API core offers the best conditions for maximizing
treatment size scalability.
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To assess the cost of each treatment portfolio, the complexity factor by Pugh [41]
was applied. The results indicated that the cost of modularization does not increase as
fast as the improvement obtained in the benefit metrics. However, as the benefit and cost
metrics are not directly comparable, value has been suggested as an approach to compare
the treatment portfolios concerning the benefit for the patient and the cost of producing
the various product variants within a treatment portfolio. Overall, the results showed that
— An increased degree of modularization (moving from portfolio A to portfolio C) can
result in faster increasing benefits compared to the increasing costs from modularization.
However, several tradeoffs between design choice concerning the degree of product
modularization and the performance metrics could be detected. A decreasing API core dose
strength promotes dose strength scalability; however, the size scalability of a treatment
portfolio suffers. Introducing additional components such as lids and cups substantially
improves the target release profile flexibility, but the cost of production increases. Further
studies should account for which design requirement is the most important to support de-
cisions regarding modular product designs and/or to conduct module design optimization
by maximizing the benefit and cost tradeoff.
This study only considered modular product designs. Process flexibility (i.e., the
feasible approach to producing increased product variety) as well as a profitable provision
(i.e., the ability to supply the customized pharmaceutical products to the patients) should be
studied along with product modularization. Ultimately, if the customized pharmaceutical
product cannot be produced and supplied profitably, it will not reach the patient, and thus
the treatment outcome cannot be enhanced.
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Appendix A. Performance Assessment
Table A1 displays the resulting raw data on assessing the resulting performance of
each treatment portfolio, reference case, A, B and C, for both the dose-dependent and
-independent scenarios. The resulting performance is assessed for the benefit-metrics, Bdose,
Brelease and Bsize as well as the cost-metric, C.
Table A1. Resulting values of calculating the performance of each treatment portfolio for the respective scenario.
Performance
Metric Reference
Dependent Release Independent Release
Portfolio A Portfolio B Portfolio C Portfolio A Portfolio B Portfolio C
Bdose 0.7909 0.9163 0.9581 0.9581 0.9163 0.9581 0.9581
Brelease 1 1 1 7.2349 7.7469 13.9962 13.9962
Bsize 1 14.2531 8.0038 11.1285 14.2531 8.0038 11.1285
C 1.6409 9.4 10.963 11.74 12.4 13.9634 14.74
Appendix B. Scales
The scales for the scoring system are displayed in Figures A1–A4. The scales are
created for each performance metric, Bdose, Brelease and Bsize and C, respectively. These scales
bases on the worst- and best-performing portfolio for each performance metric, where the
worst performance is assigned the score one and the best performance is assigned the score
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five. In between these scores, a linear scale has been created and the remaining portfolios
are assigned scores depending on where on the linear scale their performance result.
Figure A1. Scale for the Bdose performance metric.
Figure A2. Scale for the Brelease performance metric.
Figure A3. Scale for the Bsize performance metric.
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Figure A4. Scale for the C performance metric.
Appendix C. Concept Scoring
Table A2 displays the resulting scores assigned to each treatment portfolio on each
performance metric.
Table A2. The resulting scores of each treatment portfolio on the respective performance metric.
Reference
Dependent Release Independent Release
Portfolio A Portfolio B Portfolio C Portfolio A Portfolio B Portfolio C
Bdose 1.0000 4.0000 5.0000 5.0000 4.0000 5.0000 5.0000
Brelease 1.0000 1.0000 1.0000 2.9190 3.0766 5.0000 5.0000
Bsize 1.0000 5.0000 3.1139 4.0569 5.0000 3.1139 4.0569
C 5.0000 2.6306 2.1534 1.9161 1.7146 1.2371 1.000
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